pharmaphorum January 13, 2026
AbbVie has joined many of its big pharma peers by signing a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avoid tariffs – sweetened with a promise to invest $100 billion in R&D and manufacturing projects in the US over the next 10 years.
The company was one of the last remaining holdouts among a group of 17 pharma groups that were singled out by President Trump in letters ordering them to adopt MFN pricing or face tariffs on drugs imported into the US of up to 100%. Its announcement leaves Regeneron as the last of that group yet to reach an agreement.
The broad sweep of the AbbVie agreement is much the same as the others...
Today's Sponsors
Today's Sponsor